Kazia Therapeutics reports preclinical data for cancer drug NDL2 Jan 30, 2026 08:00AM
H.C. Wainwright Reiterates Buy Rating on Kazia Therapeutics (KZIA) Jan 28, 2026 06:48AM
Kazia Therapeutics regains full NASDAQ compliance Dec 22, 2025 08:02AM
Kazia Therapeutics (KZIA) PT Raised to $18 at H.C. Wainwright Dec 12, 2025 06:43AM
Kazia presents breast cancer trial data at medical conference Dec 10, 2025 08:03AM


Nov 18, 2025 04:15PM Kazia Therapeutics reports complete response in breast cancer patient
Oct 28, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Kazia Therapeutics (KZIA)
Oct 27, 2025 07:16AM Kazia plans FDA meeting on glioblastoma drug regulatory pathway
Oct 7, 2025 08:33AM Kazia Therapeutics licenses PD-L1 protein degrader for cancer treatment
Oct 2, 2025 08:31AM Kazia reports 86% tumor reduction in single breast cancer patient case
Sep 11, 2025 08:01AM Kazia reports paxalisib disrupted cancer cell clusters in lab study
Jul 10, 2025 06:42AM Kazia Therapeutics (KZIA) PT Raised to $13 at H.C. Wainwright
Jul 9, 2025 08:00AM Kazia Therapeutics reports early data from breast cancer trial patient
Jun 11, 2025 08:00AM Kazia Therapeutics (KZIA) Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer
Mar 31, 2025 07:31AM Kazia Therapeutics (KZIA) Sells IP and Trademarks Rights for Cantrixil for $1M
Feb 20, 2025 08:46AM Kazia Therapeutics (KZIA) and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation
Jan 30, 2025 07:31AM Kazia Therapeutics (KZIA) announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer
Jan 10, 2025 10:01AM Kazia Therapeutics (KZIA) Announces $2.0 Million Registered Direct Offering
Dec 31, 2024 08:00AM Kazia Therapeutics (KZIA) Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA
Nov 4, 2024 07:31AM Kazia Therapeutics (KZIA) Granted Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib
Oct 2, 2024 08:47AM Kazia Therapeutics (KZIA) Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metasta
Sep 12, 2024 07:30AM Kazia Therapeutics (KZIA) Enters Licensing Agreement with QIMR Berghofer
Jul 12, 2024 08:18AM H.C. Wainwright Reiterates Buy Rating on Kazia Therapeutics (KZIA)
Jul 10, 2024 07:30AM Kazia Therapeutics (KZIA) Reports Phase 2/3 Trial Results for Paxalisib in Glioblastoma
Jul 10, 2024 07:30AM Kazia Therapeutics (KZIA) Reports Phase 2/3 Trial Results for Paxalisib in Glioblastoma
Jun 25, 2024 06:06AM Kazia Therapeutics (KZIA) Files for 1.1M ADS Offering by Selling Stockholders